We are a newly organized, blank check company formed as a Delaware corporation for the purpose of effecting an initial business combination with one or more target businesses. We have not selected any specific target business and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any target business regarding an initial business combination with our company. While we may pursue an acquisition opportunity in any industry or sector, we intend to capitalize on our management team’s differentiated ability to source, acquire and manage a business in the life sciences industry.
Learn more about SAB Biotherapeutics’ unique immunotherapy platform and its pipeline of novel clinical and preclinical programs—click here to watch a replay of the company’s recent Virtual R&D Day
Sign up for Email Alerts
Receive updates straight into your inboxSign up today